Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a pharmaceutical company based in Irving, Texas. Founded in 2002, Reata is primarily focused on investigating experimental oral antioxidative and anti-inflammatory drugs, which dually activate the antioxidative transcription factor Nrf2 and inhibit the pro-inflammatory transcription factor NF-κB.[1]

Pipeline

The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in Reata’s portfolio.

Bardoxolone Methyl

Bardoxolone methyl was one of the first of the class of synthetic triterpenoids to be studied the clinic. It has been evaluated in Phase 1 studies for cancer,[2] Phase 2 and 3 studies for chronic kidney disease (CKD) associated with type 2 diabetes,[3][4] and is currently being evaluated in a Phase 2 study for pulmonary arterial hypertension.[5][6][7]

RTA 408

RTA 408 is a second generation member of the synthetic oleanane triterpenoid compounds and currently in clinical development. Preclinical studies have demonstrated that RTA 408 possesses antioxidative and anti-inflammatory activities,[8][9] as well as the potential to improve mitochondrial bioenergetics.[10] Because of the broad applicability of such effects across many diseases, RTA 408 is currently under clinical investigation in several Phase 2 clinical studies including immunooncology,[11] corneal endothelial cell loss associated with cataract surgery [12] Friedreich’s ataxia,[13] and mitochondrial myopathies.[14][15]

Others

Reata is also actively engaged in the discovery of small molecule disease-modifying drugs that function by stabilizing the normal three-dimensional structure of target proteins or generally enhancing the folding environment of the cell. Defects in protein folding underlie a large number of genetic diseases including certain forms of cancer, familial Alzheimer's disease, and cystic fibrosis. Protein folding defects are also believed to play important roles in the development of non-inherited forms of many of these diseases.

Partnerships

Reata has a licensing agreement with Kyowa Hakko Kirin for development and commercialization of bardoxolone methyl for CKD and related indications in Japan, China, Taiwan, Korea, and other select Southeast Asian countries.[16]

Reata also has a licensing agreement with Abbvie for development and commercialization of bardoxolone methyl outside the U.S., excluding Asian markets defined in the agreement with Kyowa Hakko Kirin.[17] Abbvie and Reata also have a second agreement for development of the second generation portfolio of synthetic oleanane triterpenoid compounds, including RTA 408, as well as other Nrf2 activators.[18]

References

  1. ↑ Sporn MB, Liby KT, Yore MM; et al. (2011). "New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress". J Nat Prod 74: 537–45. doi:10.1021/np100826q. PMC 3064114. PMID 21309592.
  2. ↑ Hong DS, Kurzrock R, Supko JG; et al. (2012). "A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas". Clin Cancer Res 18: 3396–406. doi:10.1158/1078-0432.CCR-11-2703. PMID 22634319.
  3. ↑ Pergola PE, Raskin P, Toto RD; et al. (2011). "Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes". N Engl J Med 365: 327–36. doi:10.1056/NEJMoa1105351. PMID 21699484.
  4. ↑ de Zeeuw D, Akizawa T, Audhya P; et al. (2013). "Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease". N Engl J Med 369: 2492–503. doi:10.1056/NEJMoa1306033. PMID 24206459.
  5. ↑ "Reata Begins Enrollment For PAH – LARIAT Phase 2 Study Examining Bardoxolone Methyl for Treating Pulmonary Arterial Hypertension". Retrieved 6 October 2014.
  6. ↑ "Bardoxolone Methyl Evaluation in Patients With Pulmonary Arterial Hypertension (PAH) (LARIAT)". Retrieved 6 October 2014.
  7. ↑ Carroll, John (6 October 2014). "After a taste of disaster, Reata plans a comeback for bardoxolone".
  8. ↑ Reisman SA, Lee CY, Meyer CJ; et al. (2014). "Topical application of the synthetic triterpenoid RTA 408 activates Nrf2 and induces cytoprotective genes in rat skin.". Arch Dermatol Res 306: 447–57. doi:10.1007/s00403-013-1433-7. PMID 24362512.
  9. ↑ Reisman SA, Lee CY, Meyer CJ; et al. (2014). "Topical application of the synthetic triterpenoid RTA 408 protects mice from radiation-induced dermatitis.". Radiat Res 181: 512–20. doi:10.1667/RR13578.1. PMID 24720753.
  10. ↑ Neymotin A, Calingasan NY, Wille E; et al. (2011). "Neuroprotective effect of Nrf2/ARE Activators, CDDO-ethylamide and CDDO-trifluoroethylamide in a Mouse Model of Amyotrophic Lateral Sclerosis". Free Radic Biol Med 51: 88–96. doi:10.1016/j.freeradbiomed.2011.03.027. PMC 3109235. PMID 21457778.
  11. ↑ "RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma)". Retrieved 6 October 2014.
  12. ↑ "RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD". April 15, 2015.
  13. ↑ "RTA 408 Capsules in Patients With Friedreich's Ataxia (MOXIe)". Retrieved 6 October 2014.
  14. ↑ "RTA 408 Capsules in Patients With Mitochondrial Myopathy (MOTOR)". Retrieved 6 October 2014.
  15. ↑ "Reata Announces the Initiation of Phase 2 Studies Examining RTA 408 for the Treatment of Friedreich's Ataxia and Mitochondrial Myopathies". Retrieved 6 October 2014.
  16. ↑ "Reata Pharmaceuticals Licenses Chronic Kidney Disease Drug". Retrieved 6 October 2014.
  17. ↑ "Abbott and Reata Pharmaceuticals Announce Agreement to Develop and Commercialize Bardoxolone Methyl". Retrieved 6 October 2014.
  18. ↑ Carroll, John. "UPDATED: Abbott bets $400M on mega-blockbuster future for Reata program". Retrieved 6 October 2014.

External links

This article is issued from Wikipedia - version of the Wednesday, September 02, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.